CD8A and neoplasm: TA99-HL2-KOA1 immunotherapy and Trp2Vax appeared to increase the frequencies of naïve tumor-infiltrating CD8+ T-cells but did not significantly change the frequencies of stem-like or terminally differentiated CD8+ T cells (Supplementary Figure 6G).